Asciminib Monotherapy for CML-CP Without BCR–ABL1 T315I Mutations Treated With ≥2 Prior TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Leukemia 2023 Mar 22;[EPub Ahead of Print], MJ Mauro, TP Hughes, DW Kim, D Rea, JE Cortes, A Hochhaus, K Sasaki, M Breccia, M Talpaz, O Ottmann, H Minami, YT Goh, DJ DeAngelo, MC Heinrich, V Gómez-García de Soria, P le Coutre, FX Mahon, JJWM Janssen, M Deininger, N Shanmuganathan, MB Geyer, S Cacciatore, F Polydoros, N Agrawal, M Hoch, F LangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.